Limitations, agreements, and source contact

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome · Source last updated 2025-04-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

NShort@mdanderson.org

organization

The University of Texas MD Anderson Cancer Center

phone

713-563-4485

title

Nichols Short MD/Associate Professor

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice